Heart failure module 5: special cases in heart failure

Released1 November 2017     Expires: 01 November 2019      Programme:

Anaemia in patients with heart failure

Anaemia is common in patients with heart failure. It is most often seen in women, the elderly and patients with renal dysfunction.57 It is associated with more severe symptoms, worse functional status and higher risk of morbidity and mortality.58,59

The prevalence of anaemia varies between 7–50% in study populations and heart failure registries due to varying definitions and patient selection for studies. In a systematic review of 34 studies, most of which used the World Health Organisation definition of anaemia (haemoglobin <13 g/dL for men; <12 g/dL for women), the prevalence of anaemia was 37% amongst 153,000 patients with heart failure.

When a patient with heart failure is identified as having anaemia, tests should be carried out to identify an underlying cause (occult blood loss, iron/vitamin B12/folate deficiency).21 However, often a specific cause cannot be found and the anaemia may be a consequence of multiple factors relating to the disease and co-morbidities (figure 6).

Figure 6. Causes of anaemia in patients with heart failure
Figure 6. Causes of anaemia in patients with heart failure
Chronic kidney disease

CKD is common among patients with chronic heart failure (18%).40 The primary cause of anaemia in patients with CKD is reduced erythropoietin (EPO) production but other factors, such as nutrient deficiency associated with renal dysfunction also play a role.

The prevalence of anaemia among patients with CKD is inversely proportional to estimated glomerular filtration rate (eGFR) (table 3).60

Heart failure learning module: Table 3. Prevalence of anaemia by eGFR in outpatients with CKD (n=18,474)59
Table 3. Prevalence of anaemia by eGFR in outpatients with CKD (n=18,474)60
Supression of angiotensin II activity

ACE inhibitors may also contribute to anaemia in patients with heart failure.61

  • Reduced angiotensin II activity causes dilation of the afferent arteriole of the glomerulus and increased renal blood flow which, in turn, reduces EPO secretion.
  • Angiotensin II stimulates production of red blood cell precursor cells via activation of angiotensin II receptor type 1 on blast cells.62
  • ACE inhibitors inhibit the breakdown of N-acetyl-seryl-aspartyl-lysyl-proline which suppresses haematopoetic stem cell proliferation.63
Haemodilution

Haemodilution occurs as a consequence of fluid retention in patients with heart failure,64 and is associated with anaemia in patients with heart failure independent of eGFR and EPO levels.65 It may account for as many as half the cases of anaemia in chronic heart failure.61

Effect of pro-inflammatory cytokines

Heart failure is a pro-inflammatory state associated with raised levels of tumour necrosis factor and interleukin-6 among other cytokines.66 Levels of these cytokines are inversely proportional to haemoglobin.67 Pro-inflammatory states reduce EPO secretion,68 and reduce GI absorption and the bioavailability of iron for haem production.69

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.